Live Breaking News & Updates on கடுமையான மருந்துகள் இன்க்|Page 5
Stay updated with breaking news from கடுமையான மருந்துகள் இன்க். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Rigel Reports First Quarter 2021 Financial Results and Provides Business Update - Reported positive topline results of fostamatinib in Phase 2 clinical trial in hospitalized patients with COVID-19 - Net product sales of $12.4 million and total revenues of $81.0 million - Received upfront cash payment of $125 million from Eli Lilly for the exclusive license agreement for Rigel s RIP1 inhibitor program - Conference call and webcast today at 4:30PM Eastern Time News provided by Share this article Share this article SOUTH SAN FRANCISCO, Calif., May 5, 2021 /PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2021, including sales of TAVALISSE ....
A new research study titled ” US Autoimmune Hemolytic Anemia Drugs market” successfully shows the entire scenario as well as a comprehensive overview ....
Intellia Therapeutics, Inc. (NASDAQ: NTLA) (before the market open) Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (before the market open) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) (before the market open) Insmed Incorporated (NASDAQ: INSM) (before the market open) Fulcrum Therapeutics, Inc. (NASDAQ: FULC) (before the market open) Endo International plc (NASDAQ: ENDP) (before the market open) Bio-Techne Corporation (NASDAQ: TECH) (before the market open) Harvard Bioscience, Inc. (NASDAQ: HBIO) (before the market open) Athenex, Inc. (NASDAQ: ATNX) (before the market open) Zoetis Inc. (NYSE: ZTS) (before the market open) Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (before the market open) Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) (before the market open) ....
/PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2021 financial results after market close on. ....
16% Certain financial information for 2021 and 2020 is presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add due to rounding. Reported results were prepared in accordance with U.S. generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the periods. Non-GAAP measures reflect adjustments for the items described in the reconciliation tables later in the release. Beginning in 2021, non-GAAP measures exclude gains and losses on investments in equity securities and 2020 amounts have been reclassified for comparability. The company s 2021 financial guidance is being provided on both a reported and a non-GAAP basis. The non-GAAP measures are presented to provide additional insights into the underlying trends in the company s business. ....